unistrain prrs
laboratorios hipra s.a., spānija - dzīvas novājinātas vta vīruss, celms vp-046 bis - liofilizāts un šķīdinātājs suspensijas injekcijām pagatavošanai - cūkas
nobilis cav p4 liofilizāts suspensijas injekcijām pagatavošanai
intervet international b.v., nīderlande - vistas anēmijas vīrusa celma - liofilizāts suspensijas injekcijām pagatavošanai - vistas
poulvac bursa plus
zoetis belgium s.a., beļģija - dzīvot infekcijas bursal slimības vīruss, celms v877 - liofilizāts suspensijas pagatavošanai lietošanai ar dzeramo ūdeni - vistas
gallimune 302 nd+ib+eds
merial s.a.s., francija - inaktivēta Ņūkāslas slimības vīrusa, inaktivēta infekcijas, bronhīts vīruss, inaktivēta olu piliens sindroms vīruss - ūdens-eļļas emulsija injekcijai - cāļi
porcilis begonia liofilizāts suspensijas injekcijām pagatavošanai
intervet international b.v., nīderlande - dzīvot saslimšanu's slimības vīrusa celma begonia - liofilizāts suspensijas injekcijām pagatavošanai - cūkas
tabic m.b. putojošās tabletes
phibro animal health (poland) sp. z o.o., polija - mazināt infekcijas bursal sērgas vīrusu - putojošās tabletes - vistas
v.h. + h-120 liofilizāts lietošanai dzeramajā ūdenī
phibro animal health (poland) sp. z o.o., polija - dzīvot Ņūkāslas slimības vīrusu, infekcijas putnu bronhīts vīruss, celms h120 - liofilizāts lietošanai dzeramajā ūdenī - vistas
purevax rcpch felv
boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals par kaķveidīgo, - kaķi - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.
purevax rcp felv
boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals par kaķveidīgo, - kaķi - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.
daronrix
glaxosmithkline biologicals s.a. - visu virion, inaktivēta, kas satur antigēnu*:/vjetnama/1194/2004 (h5n1)* ražots olas - influenza, human; immunization; disease outbreaks - vakcīnas - gripas profilakse oficiāli paziņotajā pandēmijas situācijā. pandēmiskās gripas vakcīna jāizmanto saskaņā ar oficiālajām vadlīnijām.